Markolf Hanefeld Selected Research

Acarbose

7/2012	Acarbose revisited for efficacy, safety and cardiovascular benefits: a key role for controlling glycemic variability.
7/2012	Conversion of IGT to type 2 diabetes mellitus is associated with incident cases of hypertension: a post-hoc analysis of the STOP-NIDDM trial.
6/2008	Effect of acarbose on vascular disease in patients with abnormal glucose tolerance.
2/2008	Acarbose: oral anti-diabetes drug with additional cardiovascular benefits.
8/2007	Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes.
5/2006	[Metabolic syndrome: "common soil" for diabetes and atherosclerosis. Novel approaches to an integrated therapy].
1/2006	Treatment of impaired glucose tolerance with acarbose and its effect on intima-media thickness: a substudy of the STOP-NIDDM trial (study to prevent non-insulin-dependent diabetes mellitus).
1/2005	Postprandial glucose regulation: new data and new implications.
5/2004	Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance.
7/2003	Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Markolf Hanefeld Research Topics

Disease

71	Type 2 Diabetes Mellitus (MODY) 12/2021 - 06/2002
19	Insulin Resistance 11/2020 - 03/2003
16	Cardiovascular Diseases (Cardiovascular Disease) 12/2021 - 07/2002
15	Glucose Intolerance 07/2014 - 06/2002
11	Inflammation (Inflammations) 12/2021 - 11/2002
11	Atherosclerosis 01/2020 - 07/2002
11	Hypoglycemia (Reactive Hypoglycemia) 08/2016 - 06/2007
11	Hyperglycemia 06/2016 - 03/2003
9	Metabolic Syndrome (Dysmetabolic Syndrome X) 12/2021 - 11/2002
9	Body Weight (Weight, Body) 01/2018 - 05/2006
7	Hypertension (High Blood Pressure) 10/2016 - 07/2003
6	Myocardial Infarction 11/2020 - 07/2007
6	Heart Failure 01/2018 - 07/2007
5	Prediabetic State (Prediabetes) 02/2021 - 10/2002
5	Diabetes Complications 11/2020 - 10/2004
4	Weight Loss (Weight Reduction) 01/2019 - 02/2012
4	Overweight 01/2019 - 02/2008
4	Dyslipidemias (Dyslipidemia) 01/2013 - 10/2002
3	Weight Gain 08/2016 - 08/2014
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 02/2021 - 01/2007
2	Hypogonadism (Hypergonadotropic Hypogonadism) 11/2020 - 01/2019
2	Stroke (Strokes) 11/2020 - 01/2020
2	Iron Deficiencies 01/2019 - 02/2018
2	Obesity 02/2018 - 10/2016
2	Vomiting 11/2017 - 11/2016
2	Nausea 11/2017 - 11/2016
2	Diabetes Mellitus 01/2012 - 06/2009
2	Vascular Diseases (Vascular Disease) 06/2008 - 04/2008
2	Coronary Disease (Coronary Heart Disease) 04/2008 - 10/2005
2	Coronary Artery Disease (Coronary Atherosclerosis) 01/2006 - 10/2002
1	Hemorrhage 12/2021
1	Chronic Disease (Chronic Diseases) 02/2021
1	Neurodegenerative Diseases (Neurodegenerative Disease) 02/2021
1	Neoplasms (Cancer) 02/2021
1	Gestational Diabetes (Gestational Diabetes Mellitus) 02/2021
1	Renal Insufficiency (Renal Failure) 02/2021
1	Erectile Dysfunction 01/2021
1	Ischemic Stroke 01/2020
1	Hypersensitivity (Allergy) 01/2019
1	Lower Urinary Tract Symptoms 01/2019

Drug/Important Bio-Agent (IBA)

42	Glucose (Dextrose)FDA LinkGeneric 02/2021 - 06/2002
18	Insulin (Novolin)FDA Link 11/2020 - 09/2005
13	Hypoglycemic Agents (Hypoglycemics)IBA 02/2021 - 05/2006
12	Metformin (Glucophage)FDA LinkGeneric 02/2021 - 01/2004
12	Pioglitazone (Actos)FDA Link 11/2014 - 01/2004
11	Acarbose FDA LinkGeneric 07/2012 - 06/2002
9	Biomarkers (Surrogate Marker)IBA 12/2021 - 01/2006
9	Blood Glucose (Blood Sugar)IBA 01/2018 - 05/2006
8	Insulin Glargine (Lantus)FDA Link 01/2017 - 05/2006
7	lixisenatideIBA 11/2017 - 05/2014
7	LipidsIBA 01/2017 - 09/2005
7	Rosiglitazone (Avandia)FDA Link 06/2011 - 02/2004
6	C-Reactive ProteinIBA 12/2021 - 01/2007
6	Pharmaceutical PreparationsIBA 11/2016 - 01/2007
6	Triglycerides (Triacylglycerol)IBA 10/2016 - 10/2002
5	dulaglutideIBA 01/2021 - 01/2018
5	HDL CholesterolIBA 10/2016 - 04/2007
5	oxidized low density lipoproteinIBA 01/2009 - 10/2002
4	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2021 - 08/2016
4	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2020 - 01/2018
4	Glucagon-Like Peptide-1 ReceptorIBA 01/2019 - 08/2014
4	ThiazolidinedionesIBA 04/2013 - 05/2006
4	Glycoside Hydrolase InhibitorsIBA 07/2012 - 07/2003
4	AdiponectinIBA 07/2011 - 07/2006
4	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 05/2011 - 08/2004
3	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 11/2014 - 09/2004
3	Proteins (Proteins, Gene)FDA Link 01/2014 - 09/2005
3	Fibrinogen (Factor I)FDA Link 04/2012 - 11/2002
3	LDL CholesterolIBA 05/2011 - 10/2002
3	Simvastatin (Zocor)FDA LinkGeneric 01/2009 - 01/2007
3	Glyburide (Glibenclamide)FDA LinkGeneric 01/2007 - 01/2005
2	Testosterone (Sustanon)FDA Link 11/2020 - 01/2019
2	IncretinsIBA 01/2020 - 01/2018
2	ferric carboxymaltoseIBA 01/2019 - 02/2018
2	CholesterolIBA 01/2014 - 01/2009
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 07/2012 - 05/2007
2	Sitagliptin Phosphate (Januvia)FDA Link 02/2012 - 06/2007
2	PPAR gammaIBA 11/2008 - 09/2004
2	Atorvastatin (Lipitor)FDA Link 04/2008 - 05/2006
2	Antihypertensive Agents (Antihypertensives)IBA 04/2008 - 05/2006
2	Glucagon (Glukagon)FDA Link 06/2007 - 09/2005
2	ProinsulinIBA 04/2007 - 01/2007
2	repaglinide (Prandin)FDA Link 01/2006 - 01/2005
1	Factor Xa InhibitorsIBA 12/2021
1	RivaroxabanIBA 12/2021
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 12/2021
1	testosterone undecanoateIBA 11/2020
1	CalciumIBA 01/2020
1	Excipients (Suspending Agents)IBA 01/2019
1	proneurotensinIBA 12/2018
1	pyroglutamyl-histidyl-glycineIBA 12/2018
1	NeurotensinIBA 12/2018
1	IronIBA 02/2018

Therapy/Procedure

17	Therapeutics 11/2020 - 01/2004
10	Glycemic Control 03/2017 - 01/2004
3	Subcutaneous Injections 01/2019 - 01/2018
2	Injections 11/2020 - 01/2018
1	Lasers (Laser) 12/2021
1	Bariatric Surgery 12/2018
1	Intravenous Infusions 02/2018